Filter your results
- 3
- 1
- 4
- 4
- 1
- 1
- 2
- 4
- 4
- 3
- 3
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TCBlood, 2015, 126 (23), pp.3979-3979
Journal articles
hal-01290424v1
|
|||
|
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC networkNeuro-Oncology, 2016, 18 (9), pp.1297-1303. ⟨10.1093/neuonc/now033⟩
Journal articles
hal-01290413v1
|
||
|
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantationEuropean Journal of Cancer, 2019, 115, pp.47-56. ⟨10.1016/j.ejca.2019.04.006⟩
Journal articles
hal-02134578v1
|
||
|
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyJournal of Clinical Oncology, 2015, 33 (33), pp.3930-3937. ⟨10.1200/JCO.2014.60.2573⟩
Journal articles
hal-01217986v1
|